A Phase 1 trial combining ibrutinib and lenalidomide in relapsed chronic lymphocytic leukemia reported durable disease control but also unexpected, serious cardiac toxicities. The study indicates that while the regimen can maintain efficacy signals, the cardiovascular risk profile may limit clinical usability. The finding adds to growing attention on cardiac adverse events across BTK inhibitor and immunomodulatory combinations, where patient selection and monitoring protocols are central to managing risk. It also suggests that future study designs may require tighter baseline cardiovascular screening or alternative dosing strategies. For clinicians, the safety signal supports a cautious approach to combination use and reinforces the need to track cardiac outcomes systematically in early-phase settings.